Research article summary (published 30 Aug 1979):

Effects of 1-alpha OH D3 therapy in uremic patients in conservative or dialytic treatment.

Full Abstract

The effects of phosphate restriction and of 1 alpha OH D3 administration were investigated in patients with advanced chronic renal failure. Few modifications of the various biochemical parameters in the patients were achieved with the restriction of dietary phosphate while better results were obtained with 1 alpha OH D3 administration. In dialyzed patients the treatment with this drug resulted in a normalization in serum calcium and alkaline phosphatase levels and in a remarkable significant decline in plasma parathyroid hormone and a reduction in the bone disease associated with uremia. This treatment in dialyzed uremic patients could avoid the employment of higher dialysate calcium concentration potentially dangerous for postdialysis hypercalcemia with the risk of metastatic calcifications.

Author information

Author/s: Lamperi, S (S); Vagge, R (R);

Journal and publication information

Publication Type: Journal Article

Journal: The International journal of artificial organs (Int J Artif Organs), published in ITALY. (Language: eng)

Reference: 1979-Sep; vol 2 (issue 5) : pp 243-7

Dates: Created 1979/11/29; Completed 1979/11/29; Revised 2004/11/17;

PMID: 478681, status: MEDLINE (last retrieved date: 2/18/2009)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MeSH Headings (categories) shown below.

Adolescent Adult Aged Alkaline Phosphatase - blood Calcium - blood Creatinine - blood Diet Female Humans

Humans Hydroxycholecalciferols - therapeutic use Hyperparathyroidism - therapy Male Middle Aged Phosphates - administration & dosage Renal Dialysis Renal Osteodystrophy - therapy Uremia - blood; diet therapy; therapy

Note: Bold headings indicate primary MeSH headings or qualifiers.

Associated Chemicals: Hydroxycholecalciferols (0) ; Phosphates (0) ; Creatinine (60-27-5) ; Calcium (7440-70-2) ; Alkaline Phosphatase (EC 3.1.3.1)

Related articles

These are the most related articles currently in our database:

• Assessment of combined 24,25(OH)2D3 and 1 alpha (OH)D3 therapy for bone disease in dialysis patients. 30 Dec 1991
• Renal osteodystrophy in dialysis patients: diagnosis and treatment. 29 Jun 1998
• Long-term treatment of uraemic osteodystrophy with 1-alpha-hydroxycholecalciferol. 30 Dec 1975
• 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease. 30 Dec 1975
• Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis. 30 Dec 1984
• 1,25-dihydroxycholecalciferol in patients with chronic renal failure. 30 Dec 1972
• Evolution of renal osteodystrophy: correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol. 30 Dec 1974
• Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure. 7 Mar 1974
• Clinical effects of 1,25-dihydroxyvitamin D3 in uremic patients with overt osteodystrophy. 30 Dec 1979

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a larger map of 100+ related articles.